-
Roche’s Rozlytrek Wins NMPA Approval for NTRK Fusion Gene-Positive Tumors
•
Swiss pharmaceutical giant Roche announced that it has received marketing approval from the National Medical Products Administration (NMPA) for its tumor-agnostic therapy Rozlytrek (entrectinib). The drug is approved for treating solid tumors in patients aged 12 and older who carry a neurotrophic tyrosine receptor kinase (NTRK) fusion gene and have…
-
Kira Pharmaceuticals’ KP104 Receives Orphan Drug Designation for PNH Treatment
•
Sino-US biotech Kira Pharmaceuticals announced that it has received an Orphan Drug Designation (ODD) from the US Food and Drug Administration (FDA) for KP104, its first-in-class biologic for the treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH). Drug ProfileKP104 is a bifunctional biologic designed to selectively block the alternative and terminal pathways…
-
Shenzhen Unveils Measures to Boost Biomedical and Medical Device Industries
•
Shenzhen’s municipal Development and Reform Commission has released a series of measures to promote the development of the city’s biomedical, medical device, and big health industry clusters. The initiatives aim to accelerate infrastructure construction, enhance clinical research capabilities, and streamline drug registration and approval processes. Infrastructure and Research Support Funding…
-
Merck’s Q2 Sales Surge 31% to USD 14.6B, Led by Keytruda and China Growth
•
US-based Merck, Sharp & Dohme (MSD, NYSE: MRK) reported Q2 2022 global sales of USD 14.6 billion, marking a 31% increase in constant exchange rate (CER) terms. The growth was driven by recovery from COVID-19 disruptions and contributions from the COVID-19 antiviral drug Lagevrio (molnupiravir). Key Growth Drivers China PerformanceChina…
-
Takeda’s Alunbrig Prescribed in China for ALK+ NSCLC Treatment
•
Japan-based Takeda Pharmaceutical Co., Ltd (TYO: 4502) announced that its lung cancer therapy Alunbrig (brigatinib) has been prescribed in China for the first time, marking its official commercialization and clinical application in the country. The drug was approved in March 2023 to treat anaplastic lymphoma kinase (ALK)-positive locally advanced or…
-
Cosmo Pharma’s Winlevi Cream Secures Greater China Licensing Deal with 3SBio
•
Ireland-based Cosmo Pharmaceuticals NV (SWX: COPN) and China’s 3SBio Inc. (HKG: 1530) have signed a licensing agreement for Cosmo’s Winlevi (clascoterone) cream 1%, a topical therapy for acne. 3SBio will hold development and commercialization rights for Winlevi in Greater China, including mainland China, Hong Kong, Taiwan, and Macao. Deal DetailsThe…
-
PerkinElmer and SCUT Launch Joint Translational Medicine Center
•
US-based PerkinElmer and China’s South China University of Technology (SCUT) have officially launched their joint translational medicine center of excellence. The center, located at SCUT’s Medical College in Guangzhou, Guangdong, is equipped with advanced scientific research tools from PerkinElmer and is open to the public. Center DetailsThe laboratory features cutting-edge…
-
Sun Pharma’s Bicalutamide Supply Suspended in Multiple Chinese Regions
•
India-based Sun Pharma has suspended the supply of its bicalutamide to Beijing, Tianjin, Jilin, Shanghai, Fujian, Henan, Yunnan, and Tibet due to non-compliance with importing standards caused by “loss on drying.” The national alliance procurement office has designated Hisun Pharma, Zhendong Pharma, and Zhaohui Pharma as the new suppliers for…
